Split-Indication Agreements: Happy Unions Or Problematic Proposals?
Executive Summary
Greater restrictions on off-label promotions and continued cost pressures are creating an environment ripe for alliances based around single products with split indications, industry executives said during the Windhover Pharmaceutical Strategic Outlook conference in New York March 27-29
You may also be interested in...
Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says
Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9
Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says
Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9
Big Pharma Gets Flexible As Licensing Activity Heats Up
Many pharmaceutical manufacturers are adopting new approaches to licensing deals as competition to fill pipelines intensifies and firms scramble to gain rights to innovative compounds and technologies